We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer's Ibrance Fails in Phase III Early Breast Cancer Study
Read MoreHide Full Article
Pfizer (PFE - Free Report) announced that an independent Data Monitoring Committee (DMC) has recommended that a large phase III PALLAS study evaluating its blockbuster drug Ibrance (palbociclib) in early breast cancer is unlikely to show statistically significant improvement in its primary endpoint of invasive disease-free survival (iDFS).
Pfizer’s shares were down more than 6% in after-hours trading on May 29, in response to the news. Pfizer’s shares have declined 2.5% this year so far compared with a decrease of 0.5% for the industry.
The study compared Ibrance plus standard adjuvant endocrine therapy to standard adjuvant endocrine therapy alone in pre- and postmenopausal women or men with HR+, HER2- early invasive (stage 2 and stage 3) breast cancer, including those at moderate-to-high risk of recurrence
The study is co-sponsored by the Austrian Breast & Colorectal Cancer Study Group and Alliance Foundation Trials along with Pfizer and involves more than 400 centers in 21 countries worldwide.
Presently, Ibrance is marketed for the treatment of HR+, HER2- advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine based therapy in postmenopausal women or in men. It is also approved in combination with AstraZeneca’s (AZN - Free Report) Faslodex (fulvestrant) for advanced breast cancer in patients with disease progression following endocrine therapy. Please note that Ibrance is not yet approved to treat any early breast cancer indication. Another phase III PENELOPE-B study is evaluating Ibrance in patients with high-risk early breast cancer. Data from the study are expected this year.
Ibrance is a key revenue driver for Pfizer and generated sales of $1.25 billion in the first quarter of 2020. The failure of the PALLAS study was a major setback for Pfizer. If Ibrance would have been approved for an early breast cancer indication, based on the PALLAS study, it would have been eligible to treat a much larger breast cancer population and bring in more revenues for Pfizer.
However, competition in the breast cancer market has risen with the launch of Eli Lilly’s (LLY - Free Report) Verzenio and Novartis’ (NVS - Free Report) Kisqali in 2-3 years. Nonetheless, in key markets like the United States, Europe and Japan, Ibrance has maintained a major market share of total CDK inhibitors class volume despite rising competition.
From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, SherazMian hand-picks one to have the most explosive upside of all.
This young company’s gigantic growth was hidden by low-volume trading, then cut short by the coronavirus. But its digital products stand out in a region where the internet economy has tripled since 2015 and looks to triple again by 2025.
Its stock price is already starting to resume its upward arc. The sky’s the limit! And the earlier you get in, the greater your potential gain.
Image: Bigstock
Pfizer's Ibrance Fails in Phase III Early Breast Cancer Study
Pfizer (PFE - Free Report) announced that an independent Data Monitoring Committee (DMC) has recommended that a large phase III PALLAS study evaluating its blockbuster drug Ibrance (palbociclib) in early breast cancer is unlikely to show statistically significant improvement in its primary endpoint of invasive disease-free survival (iDFS).
Pfizer’s shares were down more than 6% in after-hours trading on May 29, in response to the news. Pfizer’s shares have declined 2.5% this year so far compared with a decrease of 0.5% for the industry.
The study compared Ibrance plus standard adjuvant endocrine therapy to standard adjuvant endocrine therapy alone in pre- and postmenopausal women or men with HR+, HER2- early invasive (stage 2 and stage 3) breast cancer, including those at moderate-to-high risk of recurrence
The study is co-sponsored by the Austrian Breast & Colorectal Cancer Study Group and Alliance Foundation Trials along with Pfizer and involves more than 400 centers in 21 countries worldwide.
Presently, Ibrance is marketed for the treatment of HR+, HER2- advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine based therapy in postmenopausal women or in men. It is also approved in combination with AstraZeneca’s (AZN - Free Report) Faslodex (fulvestrant) for advanced breast cancer in patients with disease progression following endocrine therapy. Please note that Ibrance is not yet approved to treat any early breast cancer indication. Another phase III PENELOPE-B study is evaluating Ibrance in patients with high-risk early breast cancer. Data from the study are expected this year.
Ibrance is a key revenue driver for Pfizer and generated sales of $1.25 billion in the first quarter of 2020. The failure of the PALLAS study was a major setback for Pfizer. If Ibrance would have been approved for an early breast cancer indication, based on the PALLAS study, it would have been eligible to treat a much larger breast cancer population and bring in more revenues for Pfizer.
However, competition in the breast cancer market has risen with the launch of Eli Lilly’s (LLY - Free Report) Verzenio and Novartis’ (NVS - Free Report) Kisqali in 2-3 years. Nonetheless, in key markets like the United States, Europe and Japan, Ibrance has maintained a major market share of total CDK inhibitors class volume despite rising competition.
Pfizer currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks’ Single Best Pick to Double
From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, SherazMian hand-picks one to have the most explosive upside of all.
This young company’s gigantic growth was hidden by low-volume trading, then cut short by the coronavirus. But its digital products stand out in a region where the internet economy has tripled since 2015 and looks to triple again by 2025.
Its stock price is already starting to resume its upward arc. The sky’s the limit! And the earlier you get in, the greater your potential gain.
Click Here, See It Free >>